The Independent Standard for Pharmaceutical Reimbursement Risk
A Committee-Based Rating System Calibrated to Historical HTA Outcomes Across US and the major Pharmaceutical Markets — built for market access due diligence.
What MARA Rating Provides
MARA Rating is an independent, standardized assessment of pharmaceutical market access risk for due diligence.
Our core principle:
If this investment decision is challenged later, what independent reimbursement benchmark was relied upon?
Regulatory approval does not guarantee reimbursement.
HTA agencies and payers act as a second gate.
MARA synthesizes evidence across 10 payer-relevant domains — including comparative effectiveness, safety, cost-effectiveness, budget impact, and evidence strength — into a single, comparable rating band (A++ to C).
The objective is not to replace judgment.
It is to reduce variance, surface hidden constraints, and provide a defensible benchmark before capital is committed.
How the MARA Rating Is Determined
Structured evaluation across 10 calibrated domains
Public, verifiable evidence sources only
Committee-based judgment; no single analyst determines outcome
Minutes recorded and conflict-of-interest controls enforced
Calibrated against historical HTA outcomes
Subject to defined surveillance and rating actions
Used in High-Stakes Decision Contexts
Rating Products
MARA Ratings are designed to support:
Pre-deal due diligence and valuation stress-testing
- Licensing and BD&L assessments
Phase 2 → Phase 3 investment decisions
Pre-launch pricing and reimbursement governance
Portfolio reprioritization
Investor memoranda and capital allocation discussions
Single-Asset MARA Rating (Internal Use License)
Full committee-based rating with drivers, rationale, benchmarking, and surveillance status.
Therapeutic Area Benchmark Pack
Side-by-side rating comparison across assets within a defined therapeutic area.
Portfolio Access (Institutional License)
Structured access to multiple ratings and rating updates across defined asset groups.
Note: Public display of a MARA Rating requires a valid Display License.
Governance & Calibration
Published methodology framework
Defined rating action categories
Committee charter and conflict-of-interest controls
Calibration against retrospective HTA outcomes
Ongoing surveillance and periodic review
Rating Committee Charter
Annual Calibration Process
Obtain an independent reimbursement risk benchmark.
Contact a MARA Analyst
Have a molecule in mind—or just a market access pharma question? Send us a note to sales@mararating.com and one of our analysts will reply within one business day. All inquiries are confidential.
"*" indicates required fields
Market Access & Reimbursement Risk Insights
Gilead Acquires PepStar’s HCXT-2001 for $1.3B: What Does It Mean for Market Access?
Summary Gilead Sciences has agreed to acquire HCXT-2001. The experimental immune disease
Labor Department Finalizes Sweeping PBM Disclosure Rule: What Does It Mean for Market Access?
Summary The U.S. Department of Labor finalized a new rule on October
Most New Drugs Still Launch Above Cost-Effectiveness Thresholds, ICER Finds: What Does It Mean for Market Access?
Summary The Institute for Clinical and Economic Review (ICER) published a report